Topic: Pharmacogenetics of cancer

A special issue of Cancer Drug Resistance.

ISSN 2578-532X (Online)

Submission deadline: 31 Jan 2019

Guest Editor(s)

  • Prof. Enrico Mini, MD, PhD
    Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

    Website | E-mail

  • Dr. Stefania Nobili, PharmD, PhD

    Department of Health Sciences, University of Florence, Florence, Italy.

    Website | E-mail

Special Issue Introduction

Pharmacogenetics and pharmacogenomics has expanded rapidly over the past years and is the basis of personalized medicine. The pharmacological treatment of cancer is an ideal field for the application of pharmacogenetics into clinical practice. Testing of patients for genetic markers of efficacy or toxicity of anticancer therapy is increasingly being used as a result of clinical studies based on genotype stratification, availability of approved clinical tests and of an always more robust clinical pharmacogenetic information and guidelines.
This special issue of Cancer Drug Resistance is designed to provide an overview of the role of pharmacogenetics and pharmacogenomics in cancer treatment, including methods of discovery and clinical drug development, available information on drug labels and web resources, guidelines, with particular regard to specific cancer drug classes. Finally, the integration of somatic pharmacogenomic markers into clinical practice with examples of main cancer types will be also addressed.


Pharmacogenetics, pharmacogenomics, methodology, clinical trials, anticancer drugs, drug label information, web resources, guidelines

Submission Deadline

31 Jan 2019

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 31 Jan 2019
Contacts: Elaine Gao, Managing Editor,

The following list shows the information of planned papers to this special issue. All the papers submitted to Cancer Drug Resistance will go through a rigorous peer review. (Please note that the information below is provisional and may be subject to future change)

Planned Papers

Type: Review

Title: Opportunities and challenges of implementing Pharmacogenomics in Cancer Drug Development

Authors: Paolo Tarantino1,2 and Giuseppe Curigliano1,2

1. Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology IRCCS, Milan
2. Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy3. To whom correspondence should be sent

Abstract: Cancer drug development is a time and resources consuming process. Around 90% of drugs entering clinical trials fail due to lack of efficacy and/or occurrence of serious adverse events, many of which after hugely expensive phase III studies. Part of the discarded drugs might be beneficial only in a subgroup of the study patients, and some adverse events might be prevented by identifying those patients more vulnerable to toxicities. The implementation of pharmacogenomic biomarkers allows such categorization of patients, in order to predict efficacy and toxicity biomarkers and to optimize the drug development process. Around seventy FDA approved drugs currently present one or more genetic biomarker to keep in consideration, and with the progress of Precision Medicine (PM) tailoring therapies on individuals’ genomic landscape promises to become a new standard of cancer care. In the current article we review the role of pharmacogenomics in cancer drug development, underlying the advantages and challenges of its implementation in this setting.

Type: Review

Title: Conquering cancer drug resistance using genomic medicine - the quest for evidence

Authors: Theodoros G. Soldatos, Sajo Kaduthanam, David Jackson

Affiliations: Molecular Health GmbH, Heidelberg, Germany.

Abstract: While the application of genomic technologies to the molecular characterization of patient tumors continues to emerge as a rational and highly promising approach for guiding treatment decisions, conclusive evidence of clinical utility remains wanting. The result is an environment where innovators accrue significant financial burden and risk, whilst patients, providers, payers and regulators await evidence of clinical and pharmacoeconomic benefit. It is therefore incumbent on every exponent of clinical NGS-testing and/or treatment decision support analytics, to expeditiously and cost-effectively demonstrate the positive impact of these technologies on drug resistance/response, patient survival and/or quality of life. Here we review perspectives on the current status of these efforts globally.

Published Articles